Pyrotinib Shows Activity in HER2-Positive Non-Small Cell Lung Cancer

Share this content:
Pyrotinib showed activity in HER2-positive non-small cell lung cancer, both in preclinical experiments and in patients enrolled in a phase 2 trial.
Pyrotinib showed activity in HER2-positive non-small cell lung cancer, both in preclinical experiments and in patients enrolled in a phase 2 trial.

Pyrotinib, an irreversible pan-HER receptor tyrosine kinase inhibitor, showed activity against HER2-positive non-small cell lung cancer (NSCLC) in preclinical experiments and in a phase 2 clinical trial ( Identifier: NCT02535507).1 The results were published online December 31, 2018, in Annals of Oncology.

Study researchers conducted a series of experiments to determine the activity of pyrotinib in lung cancer. Cell viability and proliferation assays were performed on patient-derived lung cancer organoids that were exposed to pyrotinib. Compared with treatment with afatinib, pyrotinib slowed cell growth more significantly in the disease-model organoids (P = .0038). In xenograft mouse models, pyrotinib slowed tumor growth in a dose-dependent fashion and significantly shrank tumors, altogether demonstrating superior antitumor activity compared with afatinib (P = .0471) and ado-trastuzumab emtansine (T-DM1) (P = .0138).

Continue Reading Below

For the phase 2 study, 15 patients with HER2-positive NSCLC were enrolled and treated with pyrotinib 400 mg. Ten of the 15 patients had HER2 A775_G776insYVMA insertion. The primary end point of the trial was objective response rate (ORR), and secondary end points included progression-free survival (PFS).

Of the 15 patients, 8 (53.3%) had a partial response and 3 (20.0%) had stable disease, yielding an ORR of 53.3%. The median PFS was 6.4 months (95% confidence interval [CI], 1.60-11.20), with a range of 1.7 months to 23.4 months.

Among the 10 patients with HER2 A775_G776insYVMA insertion, the ORR was 50% and PFS was 4.1 months (95% CI, 1.42-6.10). Responses were also seen in patients with HER2 G776C, G776>VC, or L755P. One patient with G776>IC did not respond to treatment.

Nine patients (60%) had adverse events of any grade. No dose modifications occurred as a result of adverse events.

“Pyrotinib's encouraging antitumor activity in patients with HER2 exon 20 mutant lung cancers warrants further evaluation in an ongoing multicenter phase 2 trial,” the study authors wrote in conclusion.


  1. Wang Y, Jiang T, Qin Z, et al. HER2 exon 20 insertions in non-small cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib [published online December 31, 2018]. Ann Oncol. doi: 10.1093/annonc/mdy542

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs